SlideShare a Scribd company logo
1 of 17
Dept. Diagnostic Medicine
SMBD-JewishGeneralHospital, Montreal, Qc
New method for determining real C.difficile infections by
detecting the total bacterial load in stool samples using
the universal bacterial 16S rDNA qPCR assay
Ivan Brukner Ph.D.
Lady Davis Institute for Medical
Research
Key words: total bacterial load, stool samples, qPCR assay, normalisation
Outline
 Limitations of qualitative PCR as a tool for precise
diagnosis of infections caused by opportunistic
pathogens
 Method proposed by JGH in collaboration with McGill
University
 Results
 Conclusions
 Advantages of the Method for Focus Diagnostics
 Current IP Status
 Suggestions for next steps
Limitations of qualitative PCR as a tool
for precise diagnosis of infections caused
by opportunistic pathogens
Opportunistic pathogens:
 Infectious agent that can only cause disease when the host's resistance
is low
 Found in stool, urine, respiratory samples
Ex: C.difficile, H.pylori, Haemophilus influenzae, Streptococcus
pneumoniae
Qualiative PCR :
 Detects the presence or absence of a certain sequence
 Does not distinguish samples of symptomatic vs non symptomatic
patients with opportunistic bacteria in their microbial flora
 Ex.: Detection of C.difficile: Current PCR methods targeting Toxin B or Toxin A
and B can not distinguish with certainty the sample of a patient who has CDI from
someone who is a C.difficile carrier but has a liquid stool due to either drugs,
another pathogen or laxatives.
How can we improve the current method
for diagnosis of infections caused by
opportunistic pathogens?
We need to determine the ‘threshold’ of concentration for different pathogen of
interest in total microbial flora which will allow us to determine when an
opportunistic pathogen otherwise not causing any symptoms becomes
pathogenic and can thus cause an infection.
 Determined for each pathogen by collection non symptomatic patients
Patient with symptoms
Relative concentration>= Threshold
Carrier ( asymptomatic patient)
Relative concentration< Threshold

Threshold of relative
concentration =
lowest amount of opportunistic pathogen to cause symptoms
total amount of microbial flora
Why does mass normalisation not work
with liquid stool?
 Because swab with SAME MASS can be taken from
person having 10 diarrhea per day (each ~200-400ml
volume in total) or from carrier (normal stool)
 Stool dilution effect is making normalisation based
on mass impossible to estimate clinical impact of Ct
tox B or A with Ct>=30
Method proposed by Jewish General
Hospital (JGH) in collaboration with McGill
University
 A novel method that allows one to determine the threshold of
relative concentration for various opportunistic pathogens in total
microbial flora. Values bellow the threshold would be relevant for
asymptomatic carriers.
 Method which will allow for the adequate normalisation of analytical
signal
 This can be done only if one takes into account total microbiota
(ex: 16S universal)
 Next (inevitable) step : Quantitative microbiology?
Our Methodology for detecting total
bacterial load in C.difficile samples
 Sample study size: 500 liquid C.difficile positive
stools and 50 formed C.difficile negative stools
 Study preliminary period: January-October 2014
 Identification of patients for C.difficile screening
was performed on admission according to
established hospital infection control policies.
 For measurements of wet stool mass entering the
PCR reaction, 49 stool samples were randomly
chosen and processed.
Stool example and C.difficile
 There is no correlation between clinical sample mass (stool) and
total bacterial load
 Total bacterial load is determined by more dominant parameters (not
mass)
Ex: drug uptake, infection status/diet/immune status…
 What type of signal normalisation is important for detection of
opportunistic pathogens?
 Relative normalisation using total bacterial load in microbial flora
 The same Ct value (ex: Ct>=32) for either Toxin A and/or toxin B
could have completely different clinical meaning if the context of total
bacterial flora is different (16S qPCR Ct=12 versus Ct=22)
Summary of Results
 The quantity of stool material attached to swab during “typical”
swabbing process had an average value and standard deviation of
16.5 (+/- 9.6) mg
 “Average” stool has 1012 bacteria/gram
 The average number of bacteria entering direct qPCR assay is
~107-108.
 In individual samples, the clinical variability of total bacterial load
per swab deviates from average numbers by spanning 3 log (10)
values range.
 These deviations could have significant clinical meaning, especially in
the cases where antibiotic and/or infection-induced changes in micro
biota could be relevant for diagnosis and therapy
Comparison of bacterial load measurement techniques
Figure 1. Stool sample mass (mg of stool entering sample buffer) and Ct value of
16S rDNA universal PCR assay (R2 = -0.12, P= 0.58)
Stool mass
CTvalueof16srDNAPCR
Total bacterial load varies between individuals and
it does not correlate with the stool mass
Comparison of bacterial load measurement techniques
Figure 2. Binned total bacterial counts versus Ct values of 16S rDNA qPCR
assay done with stool swab lysis protocol (Ct values above 18 have low bacterial
load and should be considered as samples with strongly reduced micro flora).
There IS correlation between total number of
bacteria in stool sample and Ct values of our
assay
logN
Ct
Variability of the total bacterial load among clinical
samples
Figure3. Distribution of Ct values amongst 500 stool swabs using our 16S qPCR
assay
Ct values of the 16S assay
Relativenumberofsamples(total500)
How much total bacterial load vary among clinical
samples (C difficile positive)?
1000x !!!!!!
LOR LOD Average efficiency (SD) r2
Nadkarni and modifications* 1000-10E8 1000 97% (2%) >0.994
mod Clifford 10000-10E8 1000 94% (4%) >0.961
Typical RFU versus cycle diagram for stool sample
Figure 4. The 10x serial dilutions of DNA isolated from stool. Excellent
correlation for both assays is in range of 12-24 Ct units
Zone masked by ‘contamination’
Reference PCR (Nadkami and
modifications)
JGH 16s qPCR( based on Modified
Clifford method)
LOR: Linear Operative Range of the assay ALOD: Average Limit of Detection
r2-value: Correlation Coefficient SD: Standard Deviation
Conclusion
 New short qPCR for 16S rDNA has the ability to measure total
bacterial load in the clinically relevant range
 Advantages of the new qPCR
(a) the only existing PCR assay with a short amplicon for 16S rDNA
(~200bp) compatible with hydrolysis probe technology (TaqMan-like)
and direct PCR (no nucleic acid isolation)
(b) does not show any self-priming/ false priming, thus allowing confident
resulting
 Next step: Collection of ~100 non-symptomatic C diff positive
samples in order to establish the threshold which will allow one to
determine when opportunistic pathogen starts to cause symptoms.
Advantages for IVD INDUSTRY in obtaining
and incorporating this method into its current
assays
Compatibility with present qPCR chemistry (TaqMan-like)
Early IP ownership and advantage over competition (not simple to
design another 16S universal assay with such good performance, with
short amplicon and without self-priming/cross-reaction)
Covering/controlling IVD diagnostics of opportune pathogens in all
microbiota samples with this IP (stool: C difficile, VRE…respiratory:
Streptococcus Pneumonia…,urine: VRE…
Current IP status
• US provisional filed January 13th, 2014 and will be
converted into a PCT in January 2015
• Current title of the IP: METHODS, REAGENTS AND KITS
FOR THE ASSESSMENT OF CLOSTRODIUM DIFFICILE
INFECTION
• Authors: Andre Dascal, Yves Longtin, Matthew Oughton, Ivan
Brukner
Possible steps going forward
Collaboration with the team to advance this assay
Licensing the technology through the purchase of
the patent from JGH

More Related Content

What's hot

Scaldaferri F. Breath Test cosa c'è di nuovo. ASMaD 2016
Scaldaferri F. Breath Test cosa c'è di nuovo. ASMaD 2016Scaldaferri F. Breath Test cosa c'è di nuovo. ASMaD 2016
Scaldaferri F. Breath Test cosa c'è di nuovo. ASMaD 2016Gianfranco Tammaro
 
Infectious diseases
Infectious diseasesInfectious diseases
Infectious diseasesSpringer
 
WHO recommended tests of tuberculosis
WHO recommended tests of tuberculosisWHO recommended tests of tuberculosis
WHO recommended tests of tuberculosisprapulla chandra
 
Dui d in urine poster itsp
Dui d in urine poster itspDui d in urine poster itsp
Dui d in urine poster itspMark Hayward
 
The New Xpert MTB/RIF Ultra:
The New Xpert MTB/RIF Ultra:The New Xpert MTB/RIF Ultra:
The New Xpert MTB/RIF Ultra:SystemOne
 
Nanodevices for the detection of disease by Maurits de Planque
Nanodevices for the detection of disease by  Maurits de PlanqueNanodevices for the detection of disease by  Maurits de Planque
Nanodevices for the detection of disease by Maurits de Planqueonthewight
 
Nucleic acid amplification technology (nat) test
Nucleic acid amplification technology (nat) testNucleic acid amplification technology (nat) test
Nucleic acid amplification technology (nat) testMEEQAT HOSPITAL
 
Effects of GeneXpert MTB/RIF Testing and GxAlert eHealth Platforms on MDR-TB ...
Effects of GeneXpert MTB/RIF Testing and GxAlert eHealth Platforms on MDR-TB ...Effects of GeneXpert MTB/RIF Testing and GxAlert eHealth Platforms on MDR-TB ...
Effects of GeneXpert MTB/RIF Testing and GxAlert eHealth Platforms on MDR-TB ...SystemOne
 

What's hot (9)

Scaldaferri F. Breath Test cosa c'è di nuovo. ASMaD 2016
Scaldaferri F. Breath Test cosa c'è di nuovo. ASMaD 2016Scaldaferri F. Breath Test cosa c'è di nuovo. ASMaD 2016
Scaldaferri F. Breath Test cosa c'è di nuovo. ASMaD 2016
 
Infectious diseases
Infectious diseasesInfectious diseases
Infectious diseases
 
WHO recommended tests of tuberculosis
WHO recommended tests of tuberculosisWHO recommended tests of tuberculosis
WHO recommended tests of tuberculosis
 
Dui d in urine poster itsp
Dui d in urine poster itspDui d in urine poster itsp
Dui d in urine poster itsp
 
Line probe assay 26 7-15
Line probe assay 26 7-15Line probe assay 26 7-15
Line probe assay 26 7-15
 
The New Xpert MTB/RIF Ultra:
The New Xpert MTB/RIF Ultra:The New Xpert MTB/RIF Ultra:
The New Xpert MTB/RIF Ultra:
 
Nanodevices for the detection of disease by Maurits de Planque
Nanodevices for the detection of disease by  Maurits de PlanqueNanodevices for the detection of disease by  Maurits de Planque
Nanodevices for the detection of disease by Maurits de Planque
 
Nucleic acid amplification technology (nat) test
Nucleic acid amplification technology (nat) testNucleic acid amplification technology (nat) test
Nucleic acid amplification technology (nat) test
 
Effects of GeneXpert MTB/RIF Testing and GxAlert eHealth Platforms on MDR-TB ...
Effects of GeneXpert MTB/RIF Testing and GxAlert eHealth Platforms on MDR-TB ...Effects of GeneXpert MTB/RIF Testing and GxAlert eHealth Platforms on MDR-TB ...
Effects of GeneXpert MTB/RIF Testing and GxAlert eHealth Platforms on MDR-TB ...
 

Similar to C Difficile JGH Presentation_IB UNIVERSAL

Vancomycin Journal Club
Vancomycin Journal ClubVancomycin Journal Club
Vancomycin Journal ClubMegan Handley
 
Molecualr diagnostics ,comparison with roche hbv kit
Molecualr diagnostics ,comparison with roche hbv kitMolecualr diagnostics ,comparison with roche hbv kit
Molecualr diagnostics ,comparison with roche hbv kitgrace tang
 
nm.3622 Micromagnetic resonance relaxometry for rapid
nm.3622 Micromagnetic resonance relaxometry for rapidnm.3622 Micromagnetic resonance relaxometry for rapid
nm.3622 Micromagnetic resonance relaxometry for rapidBrian Peng
 
Corona update 11 :: TESTING FOR CORONA VIRUS
Corona update 11 :: TESTING FOR CORONA VIRUSCorona update 11 :: TESTING FOR CORONA VIRUS
Corona update 11 :: TESTING FOR CORONA VIRUSNARENDRA MALHOTRA
 
Newer investigations of tuberculosis
Newer investigations of tuberculosisNewer investigations of tuberculosis
Newer investigations of tuberculosisVishnu Ambareesh
 
Molecular screening assay must have sample adequacy control
Molecular screening assay must have sample adequacy controlMolecular screening assay must have sample adequacy control
Molecular screening assay must have sample adequacy controlIvan Brukner
 
Antibiotic-pathogen-biomarker screening by PCR must have SAC
Antibiotic-pathogen-biomarker screening by PCR must have SACAntibiotic-pathogen-biomarker screening by PCR must have SAC
Antibiotic-pathogen-biomarker screening by PCR must have SACIvan Brukner
 
Assay-for-estimating-total-bacterial-load-relative-qPCR-normalisation-of-bact...
Assay-for-estimating-total-bacterial-load-relative-qPCR-normalisation-of-bact...Assay-for-estimating-total-bacterial-load-relative-qPCR-normalisation-of-bact...
Assay-for-estimating-total-bacterial-load-relative-qPCR-normalisation-of-bact...Ivan Brukner
 
Importance of real time pcr in diagnosis of infectious diseases
Importance of real time pcr in diagnosis of infectious diseasesImportance of real time pcr in diagnosis of infectious diseases
Importance of real time pcr in diagnosis of infectious diseasesCentral Govt, India
 
labaratory diagnosis of tuberulosis.
labaratory diagnosis of tuberulosis.labaratory diagnosis of tuberulosis.
labaratory diagnosis of tuberulosis.Tarun Prudvi Betha
 
Prevalence of Rota Virus Detection by Reverse TranscriptasePolymerase Chain R...
Prevalence of Rota Virus Detection by Reverse TranscriptasePolymerase Chain R...Prevalence of Rota Virus Detection by Reverse TranscriptasePolymerase Chain R...
Prevalence of Rota Virus Detection by Reverse TranscriptasePolymerase Chain R...IOSRJPBS
 
Detection of hepatitis b virus dna among abdominal typhus patients with hepat...
Detection of hepatitis b virus dna among abdominal typhus patients with hepat...Detection of hepatitis b virus dna among abdominal typhus patients with hepat...
Detection of hepatitis b virus dna among abdominal typhus patients with hepat...Alexander Decker
 
Molecular tests to detect human papillomavirus
Molecular tests to detect human papillomavirusMolecular tests to detect human papillomavirus
Molecular tests to detect human papillomavirusTariq Mohammed
 
Plex ID Congrès SJBM Marseille 2013
Plex ID Congrès SJBM Marseille 2013Plex ID Congrès SJBM Marseille 2013
Plex ID Congrès SJBM Marseille 2013SJBioMed
 

Similar to C Difficile JGH Presentation_IB UNIVERSAL (20)

Vancomycin Journal Club
Vancomycin Journal ClubVancomycin Journal Club
Vancomycin Journal Club
 
Molecualr diagnostics ,comparison with roche hbv kit
Molecualr diagnostics ,comparison with roche hbv kitMolecualr diagnostics ,comparison with roche hbv kit
Molecualr diagnostics ,comparison with roche hbv kit
 
nm.3622 Micromagnetic resonance relaxometry for rapid
nm.3622 Micromagnetic resonance relaxometry for rapidnm.3622 Micromagnetic resonance relaxometry for rapid
nm.3622 Micromagnetic resonance relaxometry for rapid
 
Lab diagnosis of TB
Lab diagnosis of TBLab diagnosis of TB
Lab diagnosis of TB
 
Corona update 11 :: TESTING FOR CORONA VIRUS
Corona update 11 :: TESTING FOR CORONA VIRUSCorona update 11 :: TESTING FOR CORONA VIRUS
Corona update 11 :: TESTING FOR CORONA VIRUS
 
NDBD
NDBDNDBD
NDBD
 
Newer investigations of tuberculosis
Newer investigations of tuberculosisNewer investigations of tuberculosis
Newer investigations of tuberculosis
 
Ojchd.000536
Ojchd.000536Ojchd.000536
Ojchd.000536
 
Molecular screening assay must have sample adequacy control
Molecular screening assay must have sample adequacy controlMolecular screening assay must have sample adequacy control
Molecular screening assay must have sample adequacy control
 
Antibiotic-pathogen-biomarker screening by PCR must have SAC
Antibiotic-pathogen-biomarker screening by PCR must have SACAntibiotic-pathogen-biomarker screening by PCR must have SAC
Antibiotic-pathogen-biomarker screening by PCR must have SAC
 
covid -19.pptx
covid -19.pptxcovid -19.pptx
covid -19.pptx
 
Assay-for-estimating-total-bacterial-load-relative-qPCR-normalisation-of-bact...
Assay-for-estimating-total-bacterial-load-relative-qPCR-normalisation-of-bact...Assay-for-estimating-total-bacterial-load-relative-qPCR-normalisation-of-bact...
Assay-for-estimating-total-bacterial-load-relative-qPCR-normalisation-of-bact...
 
220620-FEMS-2022-FQ_final.pdf
220620-FEMS-2022-FQ_final.pdf220620-FEMS-2022-FQ_final.pdf
220620-FEMS-2022-FQ_final.pdf
 
Importance of real time pcr in diagnosis of infectious diseases
Importance of real time pcr in diagnosis of infectious diseasesImportance of real time pcr in diagnosis of infectious diseases
Importance of real time pcr in diagnosis of infectious diseases
 
labaratory diagnosis of tuberulosis.
labaratory diagnosis of tuberulosis.labaratory diagnosis of tuberulosis.
labaratory diagnosis of tuberulosis.
 
Prevalence of Rota Virus Detection by Reverse TranscriptasePolymerase Chain R...
Prevalence of Rota Virus Detection by Reverse TranscriptasePolymerase Chain R...Prevalence of Rota Virus Detection by Reverse TranscriptasePolymerase Chain R...
Prevalence of Rota Virus Detection by Reverse TranscriptasePolymerase Chain R...
 
Detection of hepatitis b virus dna among abdominal typhus patients with hepat...
Detection of hepatitis b virus dna among abdominal typhus patients with hepat...Detection of hepatitis b virus dna among abdominal typhus patients with hepat...
Detection of hepatitis b virus dna among abdominal typhus patients with hepat...
 
Diagnosis of HIV and HCV
Diagnosis of HIV and HCVDiagnosis of HIV and HCV
Diagnosis of HIV and HCV
 
Molecular tests to detect human papillomavirus
Molecular tests to detect human papillomavirusMolecular tests to detect human papillomavirus
Molecular tests to detect human papillomavirus
 
Plex ID Congrès SJBM Marseille 2013
Plex ID Congrès SJBM Marseille 2013Plex ID Congrès SJBM Marseille 2013
Plex ID Congrès SJBM Marseille 2013
 

C Difficile JGH Presentation_IB UNIVERSAL

  • 1. Dept. Diagnostic Medicine SMBD-JewishGeneralHospital, Montreal, Qc New method for determining real C.difficile infections by detecting the total bacterial load in stool samples using the universal bacterial 16S rDNA qPCR assay Ivan Brukner Ph.D. Lady Davis Institute for Medical Research Key words: total bacterial load, stool samples, qPCR assay, normalisation
  • 2. Outline  Limitations of qualitative PCR as a tool for precise diagnosis of infections caused by opportunistic pathogens  Method proposed by JGH in collaboration with McGill University  Results  Conclusions  Advantages of the Method for Focus Diagnostics  Current IP Status  Suggestions for next steps
  • 3. Limitations of qualitative PCR as a tool for precise diagnosis of infections caused by opportunistic pathogens Opportunistic pathogens:  Infectious agent that can only cause disease when the host's resistance is low  Found in stool, urine, respiratory samples Ex: C.difficile, H.pylori, Haemophilus influenzae, Streptococcus pneumoniae Qualiative PCR :  Detects the presence or absence of a certain sequence  Does not distinguish samples of symptomatic vs non symptomatic patients with opportunistic bacteria in their microbial flora  Ex.: Detection of C.difficile: Current PCR methods targeting Toxin B or Toxin A and B can not distinguish with certainty the sample of a patient who has CDI from someone who is a C.difficile carrier but has a liquid stool due to either drugs, another pathogen or laxatives.
  • 4. How can we improve the current method for diagnosis of infections caused by opportunistic pathogens? We need to determine the ‘threshold’ of concentration for different pathogen of interest in total microbial flora which will allow us to determine when an opportunistic pathogen otherwise not causing any symptoms becomes pathogenic and can thus cause an infection.  Determined for each pathogen by collection non symptomatic patients Patient with symptoms Relative concentration>= Threshold Carrier ( asymptomatic patient) Relative concentration< Threshold  Threshold of relative concentration = lowest amount of opportunistic pathogen to cause symptoms total amount of microbial flora
  • 5. Why does mass normalisation not work with liquid stool?  Because swab with SAME MASS can be taken from person having 10 diarrhea per day (each ~200-400ml volume in total) or from carrier (normal stool)  Stool dilution effect is making normalisation based on mass impossible to estimate clinical impact of Ct tox B or A with Ct>=30
  • 6. Method proposed by Jewish General Hospital (JGH) in collaboration with McGill University  A novel method that allows one to determine the threshold of relative concentration for various opportunistic pathogens in total microbial flora. Values bellow the threshold would be relevant for asymptomatic carriers.  Method which will allow for the adequate normalisation of analytical signal  This can be done only if one takes into account total microbiota (ex: 16S universal)  Next (inevitable) step : Quantitative microbiology?
  • 7. Our Methodology for detecting total bacterial load in C.difficile samples  Sample study size: 500 liquid C.difficile positive stools and 50 formed C.difficile negative stools  Study preliminary period: January-October 2014  Identification of patients for C.difficile screening was performed on admission according to established hospital infection control policies.  For measurements of wet stool mass entering the PCR reaction, 49 stool samples were randomly chosen and processed.
  • 8. Stool example and C.difficile  There is no correlation between clinical sample mass (stool) and total bacterial load  Total bacterial load is determined by more dominant parameters (not mass) Ex: drug uptake, infection status/diet/immune status…  What type of signal normalisation is important for detection of opportunistic pathogens?  Relative normalisation using total bacterial load in microbial flora  The same Ct value (ex: Ct>=32) for either Toxin A and/or toxin B could have completely different clinical meaning if the context of total bacterial flora is different (16S qPCR Ct=12 versus Ct=22)
  • 9. Summary of Results  The quantity of stool material attached to swab during “typical” swabbing process had an average value and standard deviation of 16.5 (+/- 9.6) mg  “Average” stool has 1012 bacteria/gram  The average number of bacteria entering direct qPCR assay is ~107-108.  In individual samples, the clinical variability of total bacterial load per swab deviates from average numbers by spanning 3 log (10) values range.  These deviations could have significant clinical meaning, especially in the cases where antibiotic and/or infection-induced changes in micro biota could be relevant for diagnosis and therapy
  • 10. Comparison of bacterial load measurement techniques Figure 1. Stool sample mass (mg of stool entering sample buffer) and Ct value of 16S rDNA universal PCR assay (R2 = -0.12, P= 0.58) Stool mass CTvalueof16srDNAPCR Total bacterial load varies between individuals and it does not correlate with the stool mass
  • 11. Comparison of bacterial load measurement techniques Figure 2. Binned total bacterial counts versus Ct values of 16S rDNA qPCR assay done with stool swab lysis protocol (Ct values above 18 have low bacterial load and should be considered as samples with strongly reduced micro flora). There IS correlation between total number of bacteria in stool sample and Ct values of our assay logN Ct
  • 12. Variability of the total bacterial load among clinical samples Figure3. Distribution of Ct values amongst 500 stool swabs using our 16S qPCR assay Ct values of the 16S assay Relativenumberofsamples(total500) How much total bacterial load vary among clinical samples (C difficile positive)? 1000x !!!!!!
  • 13. LOR LOD Average efficiency (SD) r2 Nadkarni and modifications* 1000-10E8 1000 97% (2%) >0.994 mod Clifford 10000-10E8 1000 94% (4%) >0.961 Typical RFU versus cycle diagram for stool sample Figure 4. The 10x serial dilutions of DNA isolated from stool. Excellent correlation for both assays is in range of 12-24 Ct units Zone masked by ‘contamination’ Reference PCR (Nadkami and modifications) JGH 16s qPCR( based on Modified Clifford method) LOR: Linear Operative Range of the assay ALOD: Average Limit of Detection r2-value: Correlation Coefficient SD: Standard Deviation
  • 14. Conclusion  New short qPCR for 16S rDNA has the ability to measure total bacterial load in the clinically relevant range  Advantages of the new qPCR (a) the only existing PCR assay with a short amplicon for 16S rDNA (~200bp) compatible with hydrolysis probe technology (TaqMan-like) and direct PCR (no nucleic acid isolation) (b) does not show any self-priming/ false priming, thus allowing confident resulting  Next step: Collection of ~100 non-symptomatic C diff positive samples in order to establish the threshold which will allow one to determine when opportunistic pathogen starts to cause symptoms.
  • 15. Advantages for IVD INDUSTRY in obtaining and incorporating this method into its current assays Compatibility with present qPCR chemistry (TaqMan-like) Early IP ownership and advantage over competition (not simple to design another 16S universal assay with such good performance, with short amplicon and without self-priming/cross-reaction) Covering/controlling IVD diagnostics of opportune pathogens in all microbiota samples with this IP (stool: C difficile, VRE…respiratory: Streptococcus Pneumonia…,urine: VRE…
  • 16. Current IP status • US provisional filed January 13th, 2014 and will be converted into a PCT in January 2015 • Current title of the IP: METHODS, REAGENTS AND KITS FOR THE ASSESSMENT OF CLOSTRODIUM DIFFICILE INFECTION • Authors: Andre Dascal, Yves Longtin, Matthew Oughton, Ivan Brukner
  • 17. Possible steps going forward Collaboration with the team to advance this assay Licensing the technology through the purchase of the patent from JGH